(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation. Read More
(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder. Read More
(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines. Read More
(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November. Read More
(Alliance News) - AstraZeneca PLC may need to offer some margin certainty for its shares to push higher, despite it having a decent top-line growth outlook, investment bank Jefferies said. Read More
AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752. Read More
(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes. Read More
(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures. Read More
(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer. Read More
(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint. Read More
(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date. Read More
(Alliance News) - AstraZeneca PLC on Thursday said it struck a licence deal in the weight loss drug space, giving something to think about for Novo Nordisk AS, whose Ozempic and Wegovy products have laid down the gauntlet for the rest of the pharma space. Read More
(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu. Read More